반응 #166

ord-1d2fdaa081974f57a1f1449ebd3c7c9a

반응 방정식

FC(F)(F)c1ccnc(Br)c1
FC(F)(F)c1ccnc(Br)c1
CC(C)(C)OC(=O)N1CCC(CN=C(c2ccccc2)c2ccccc2)(C(N)=O)CC1
CC(C)(C)OC(=O)N1CCC(
CC(C)(C)OC(=O)N1CCC(CN=C(c2ccccc2)c2ccccc2)(C(=O)Nc2cc(C(F)(F)F)ccn2)CC1
CC(C)(C)OC(=O)N1CCC(
수율 71.4%

용매

반응 조건

온도
90°CELSIUS

실험 절차

tert-butyl 4-carbamoyl-4-((diphenylmethyleneamino)methyl)piperidine-1-carboxylate (500 mg, 1.19 mmol), 2-bromo-4-(trifluoromethyl)pyridine (268 mg, 1.19 mmol), and cesium carbonate (541 mg, 1.66 mmol) were suspended in dioxane (2 mL) . The reaction was purged with nitrogen for 10 minutes then 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene (30.9 mg, 0.05 mmol) and palladium(II) acetate (7.99 mg, 0.04 mmol) were added. The reaction was heated at 90 °C for 48 hours. The reaction was cooled to room temperature, diluted with DCM, filtered and concentrated. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford tert-butyl 4-((diphenylmethyleneamino)methyl)-4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)piperidine-1-carboxylate (480 mg, 71.4 %) as a white solid.

출처

750 AstraZeneca ELN dataset